Gastrointestinal Cancers News

Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer

Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer

A clinical trial found a potential marker to identify the patients with advanced esophageal squamous cell carcinoma who were most likely to respond to nivolumab.

HER2 Amplification in Brain Metastases May Be Relatively Common in GI Cancer

HER2 Amplification in Brain Metastases May Be Relatively Common in GI Cancer

Brain metastases were HER2-positive in nearly one-third of patients with gastrointestinal primary malignancies, suggesting molecular testing may be prudent.

Long-Term Surgical Outcomes for Rectal Cancer Survivors Elucidated in Study

Long-Term Surgical Outcomes for Rectal Cancer Survivors Elucidated in Study

Participant characteristics were similar between surgical treatment groups.

Patient Evaluation of Quality in GI Cancer Surgery

Patient Evaluation of Quality in GI Cancer Surgery

Patient-reported quality measures, collected from those who underwent surgery for GI cancer, offered clinicians valuable insight into care management.

Study Found Worse Survival for Patients with Familial Colorectal Cancer Type X

Study Found Worse Survival for Patients with Familial Colorectal Cancer Type X

In patients who developed CRC, those who had familial CRC type X were found to have worse survival outcomes than those who had Lynch syndrome.

BRCA1 Mutation Observed to Confer Heightened Risk of Colorectal Cancer

BRCA1 Mutation Observed to Confer Heightened Risk of Colorectal Cancer

A systematic review and meta-analysis determined that carriers for a mutation to BRCA1, but not BRCA2, have an increased risk of colorectal cancer.

MET Inhibitor as a Monotherapy in GI Cancers: Unlikely Beneficial

MET Inhibitor as a Monotherapy in GI Cancers: Unlikely Beneficial

The study was halted when patient response rates were lower than those seen across a similar trial involving the drug.

Bevacizumab Biosimilar Deemed Bioequivalent to Reference Drug in Metastatic CRC

Bevacizumab Biosimilar Deemed Bioequivalent to Reference Drug in Metastatic CRC

Both the reference product and its biosimilar confer to same benefit, according to research results.

Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma

Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma

Cabozantinib prolonged survival in relapsed HCC across a range of AFP levels, but a larger treatment benefit was observed with higher baseline AFP.

Native Puerto Ricans Are at Increased Risk for Certain Cancers

Native Puerto Ricans Are at Increased Risk for Certain Cancers

Cancer occurrence in island Puerto Ricans and Puerto Ricans living in the continental US and Hawaii differ considerably.

Novel Surrogate End Point Proposed in Hepatocellular Carcinoma

Novel Surrogate End Point Proposed in Hepatocellular Carcinoma

Sustained response duration, as opposed to complete or partial response, may be a better predictor of overall survival in HCC following cTACE.

FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma

FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma

The FDA based its approval on data from the REFLECT phase 3 study in which investigators enrolled 954 previously untreated patients with metastatic or unresectable hepatocellular carcinoma.

Breakthrough Therapy Designation for Encorafenib, Binimetinib, Cetuximab in BRAFV600E-Mutant CRC

Breakthrough Therapy Designation for Encorafenib, Binimetinib, Cetuximab in BRAFV600E-Mutant CRC

Results from a safety lead-in phase conducted prior to a phase 3 trial examining the safety and tolerability of encorafenib, binimetinib, and cetuximab in combination led the FDA to assign the regimen a breakthrough therapy designation.

First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

Twenty-three systemic therapy-naive patients with advanced hepatocellular carcinoma received atezolizumab plus bevacizumab every 3 weeks.

FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

The FDA based its approval on evidence from the ongoing, non-randomized CheckMate-142 phase 2 study, for which researchers treated 119 patients with nivolumab plus ipilimumab.

Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer

Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer

Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.

Real-World Study Reports PFS and OS in Metastatic CRC

Real-World Study Reports PFS and OS in Metastatic CRC

A Merck-funded study examines survival data on patients with metastatic colorectal cancer; results were presented during ESMO 2018.

Benefit of Ramucirumab in Relapsed Hepatocellular Carcinoma Confirmed in Pooled Analysis

Benefit of Ramucirumab in Relapsed Hepatocellular Carcinoma Confirmed in Pooled Analysis

Ramucirumab prolonged progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory hepatocellular carcinoma (HCC).

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs